Cadonilimab - Akeso Biopharma
Alternative Names: AK-104Latest Information Update: 20 Jun 2025
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Chipscreen Biosciences; Hunan Cancer Hospital; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University; University of Texas Southwestern Medical Center
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Registered Gastric cancer
- Preregistration Oesophageal cancer
- Phase III Liver cancer; Non-small cell lung cancer
- Phase II Cholangiocarcinoma; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Renal cell carcinoma; Solid tumours; Vulvovaginal cancer
- Phase I/II Adenocarcinoma; Malignant melanoma; Peripheral T-cell lymphoma; Small cell lung cancer
Most Recent Events
- 16 Jun 2025 Akeso Biopharma plans a phase-III trial for Adenocarcinoma (Combination therapy, Neoadjuvant, Adjuvant) in China (IV), (NCT07023315)
- 31 May 2025 Registered for Cervical cancer (First-line therapy, Combination therapy, Late-stage disease, Recurrent, Metastatic disease) in China (IV)
- 22 May 2025 Akeso plans a phase II trial for Liver cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) (IV) (NCT06984718)